Obermatt
See Similar Stocks →

Kaken Pharmaceutical

TYO:4521 · JP3207000005
PharmaceuticalsMedium

360

27
EV / EBIT4
Price / Owner Earnings14
Owner Earnings Yield62
Dividend Yield100
Price/Sales35
EV / Gross Profit77
Price/Book79
Return on Capital41
Cash Return on Capital51
Return on Equity51
EBIT Margin27
Gross Profitability50
Cash Conversion1
Accruals25
Owner Earnings Margin49
Sales growth13
Profit Growth3
Long-Term EPS Growth12
Reinvestment13
Price momentum74
Debt load89
Refinancing36
Debt Payback100
Liquidity4
Analyst ratings12
Opinion Changes50
Price Target Upside10
Market mood82
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kaken Pharmaceutical doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryJapan
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeTSE
Founded1948
Employees4
Websitekaken.co.jp
ISINJP3207000005
Last UpdateApr 2, 2026
Index & Theme
UrologyPain ManagementDermatologyManufacturingMedical DevicePharmaceutical

Description

Analysis

Middle-of-the-road

Kaken Pharmaceutical Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 55.3×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is sturdy. The company scores 0/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

Flags to be aware of: Some accounting patterns deserve a closer look. Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
30
2023202420252026

All-time high

61

Jan 2023

All-time low

17

Mar 2026

Average rank

42

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
35
33
53
41
Price/Earnings
3
24
60
86
Price/Book
79
74
86
71
Dividend Yield
100
82
94
94
Value (overall)
47
48
84
75

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kaken Pharmaceutical with its peers
Handok
KSC:002390
15
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Dong-A Socio
KSC:000640
85
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
J. B. Chemicals & Pharmaceuticals
NSI:JBCHEPHARM
69
CountrySingapore
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Formosa Laboratories
TAI:4746
63
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Otsukas
TYO:4578
71
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
SCI Pharmtech
TAI:4119
7
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →